• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email
    SC 13G/A 1 c110565_sc13ga.htm
     
         
      SECURITIES AND EXCHANGE
    COMMISSION
     
      Washington, D.C. 20549  

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Biodexa Pharmaceuticals PLC

    (Name of Issuer)

     

    American Depositary Shares, each representing 400 Ordinary Shares

    (Title of Class of Securities)

     

    59564R708**

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the ordinary shares, nominal value £0.001 per share, of the Issuer (the “Ordinary Shares”). CUSIP number 59564R708 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are listed on the Nasdaq Capital Market under the symbol “BDRX.” Each ADS represents four hundred (400) Ordinary Shares. 

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     
    CUSIP No: 59564R708
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With    
    (5) Sole Voting Power
    0 American Depositary Shares
     
    (6)

    Shared Voting Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
    (7) Sole Dispositive Power
    0 American Depositary Shares
     
    (8)

    Shared Dispositive Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.26%
      (12) Type of Reporting Person (See Instructions)
    OO
     
    CUSIP No: 59564R708
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With    
    (5)

    Sole Voting Power

    0 American Depositary Shares

    68198.64 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
    (6)

    Shared Voting Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
    (7)

    Sole Dispositive Power
    0 American Depositary Shares

    68198.64 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
    (8)

    Shared Dispositive Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0 American Depositary Shares

    112077.6 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.67%
      (12) Type of Reporting Person (See Instructions)
    IN; HC
     
    CUSIP No: 59564R708
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With    
    (5) Sole Voting Power
    0 American Depositary Shares
     
    (6)

    Shared Voting Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
    (7) Sole Dispositive Power
    0 American Depositary Shares
     
    (8)

    Shared Dispositive Power
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

     
      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    0 American Depositary Shares

    43878.96 American Depositary Shares issuable upon exercise of Warrants (See Item 4)

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    0.26%
      (12) Type of Reporting Person (See Instructions)
    IN
     
    CUSIP No: 59564R708

     This Amendment No. 1 (this “Amendment”) amends the statement on Schedule 13G filed on August 8, 2024 (the “Original Schedule 13G”) with respect to the American Depositary Shares (“ADSs”), each representing 400 Ordinary Shares, nominal value £0.001 per share, of Biodexa Pharmaceuticals PLC (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates Item 4 and Item 5 in their entirety as set forth below.

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 6,658,038,922 Ordinary Shares (represented by 16,645,097 ADSs) issued and outstanding as represented on the Company’s website as of November 12, 2024, and further assumes the exercise of the Company’s warrants (collectively, the “Reported Warrants”).

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held 0 ADSs and Reported Warrants to purchase 43878.96 ADSs and Iroquois Capital Investment Group LLC (“ICIG”) held 0 ADSs and Reported Warrants to purchase 68198.64 ADSs.

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all Ordinary Shares (and ADSs) held by and underlying the Reported Warrants held by, Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all Ordinary Shares (and ADSs) held by and underlying the Reported Warrants held by, Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of Ordinary Shares (or ADSs) owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Ordinary Shares (and ADSs) except to the extent of their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   x

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
           
      By:    /s/ Richard Abbe  
                Richard Abbe, President  
           
        /s/ Richard Abbe  
      Richard Abbe  
         
        /s/ Kimberly Page  
      Kimberly Page  
         
    523152332v.1    
     
    Get the next $BDRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BDRX

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

      Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

      2/8/24 7:21:49 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/20/24 11:56:39 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/14/24 5:12:47 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/12/24 4:30:48 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:50 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:11 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:01 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADR Ratio Change

      July 15, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be July 31, 2025. Pursuant to the Ratio Change, ADR holders will be required on a mandato

      7/15/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

      July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the gastrointesti

      7/14/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of Annual General Meeting

      June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms. About Biodexa Pharmaceutica

      6/27/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Biodexa Appoints Ann Merchant to the Board of Directors

      Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

      12/29/23 4:05:00 AM ET
      $ALVO
      $BDRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BDRX
    Financials

    Live finance-specific insights

    See more
    • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

      CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

      11/21/24 7:35:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care